1st Quarter - Report

EXPRESS SCRIPTS, INC. for EXPRESS SCRIPTS, INC.

Firm
Client
Income
—
Expenses
$445,817
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Postal POS

Postal Reform proposals and their impact on 6 day mail delivery (continuing resolution)

LobbyistCovered position, as disclosed
GARY J KLINE New Office of Congressman Brian Bilbray
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE; Government Accountability Office (GAO); White House Office; HOUSE OF REPRESENTATIVES; Internal Revenue Service (IRS); Federal Trade Commission (FTC); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Congressional Budget Office (CBO); Health Resources & Services Administration (HRSA); Labor, Dept of (DOL)

Labor Issues/Antitrust/Workplace LBR

Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)

LobbyistCovered position, as disclosed
GARY J KLINE New Office of Congressman Brian Bilbray
ROBERT W LIVELY —
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Centers For Medicare and Medicaid Services (CMS); Federal Trade Commission (FTC); Health & Human Services, Dept of (HHS); Government Accountability Office (GAO); White House Office; HOUSE OF REPRESENTATIVES; Congressional Budget Office (CBO); Health Resources & Services Administration (HRSA); SENATE; Labor, Dept of (DOL); Internal Revenue Service (IRS); Executive Office of the President (EOP); Food & Drug Administration (FDA)

Bills named: H.R. 1188 (113th)

Health Issues HCR

Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).

LobbyistCovered position, as disclosed
GARY J KLINE New Office of Congressman Brian Bilbray
ROBERT W LIVELY —
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC); SENATE; White House Office; Executive Office of the President (EOP); Congressional Budget Office (CBO); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Labor, Dept of (DOL); Centers For Medicare and Medicaid Services (CMS); Government Accountability Office (GAO); Internal Revenue Service (IRS); Health & Human Services, Dept of (HHS)

Medicare/Medicaid MMM

Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions.

LobbyistCovered position, as disclosed
GARY J KLINE New Office of Congressman Brian Bilbray
ROBERT W LIVELY —
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: White House Office; Government Accountability Office (GAO); SENATE; Health & Human Services, Dept of (HHS); Federal Trade Commission (FTC); Labor, Dept of (DOL); Centers For Medicare and Medicaid Services (CMS); Congressional Budget Office (CBO); Health Resources & Services Administration (HRSA); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Internal Revenue Service (IRS); Food & Drug Administration (FDA)

Pharmacy PHA

Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse. General issues dealing with pharmacy drug compounding.

LobbyistCovered position, as disclosed
GARY J KLINE New Office of Congressman Brian Bilbray
ROBERT W LIVELY —
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Federal Trade Commission (FTC); SENATE; Government Accountability Office (GAO); Labor, Dept of (DOL); White House Office; Centers For Medicare and Medicaid Services (CMS); Internal Revenue Service (IRS); Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Executive Office of the President (EOP)

Bills named: H.R. 1367 (113th)

Defense DEF

Pharmacy issues related to Section 700 (Champus provisions) of the annual defense bill

LobbyistCovered position, as disclosed
NANCY GILBRIDE —
GARY J KLINE New Office of Congressman Brian Bilbray
ROBERT W LIVELY —
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Health Resources & Services Administration (HRSA); White House Office; SENATE; Labor, Dept of (DOL); Internal Revenue Service (IRS); Government Accountability Office (GAO); Congressional Budget Office (CBO); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Federal Trade Commission (FTC); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Taxation/Internal Revenue Code TAX

Regulatory implementation of various tax provisions in the health reform legislation

LobbyistCovered position, as disclosed
GARY J KLINE New Office of Congressman Brian Bilbray
ROBERT W LIVELY —
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: White House Office; Federal Trade Commission (FTC); SENATE; Government Accountability Office (GAO); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Internal Revenue Service (IRS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Executive Office of the President (EOP); Congressional Budget Office (CBO); Health Resources & Services Administration (HRSA); Labor, Dept of (DOL)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.